DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,090 filers reported holding DANAHER CORPORATION in Q2 2016. The put-call ratio across all filers is 0.21 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $3,106,000 | -24.1% | 10,590 | -14.8% | 0.84% | -7.3% |
Q4 2021 | $4,090,000 | -86.3% | 12,430 | -87.3% | 0.91% | -19.3% |
Q3 2021 | $29,878,000 | +13.4% | 98,140 | -0.1% | 1.12% | +13.8% |
Q2 2021 | $26,353,000 | +19.1% | 98,200 | -0.1% | 0.99% | +9.3% |
Q1 2021 | $22,125,000 | +1.2% | 98,300 | -0.1% | 0.90% | -3.1% |
Q4 2020 | $21,853,000 | -18.3% | 98,375 | -20.8% | 0.93% | -27.5% |
Q3 2020 | $26,752,000 | +21.8% | 124,235 | 0.0% | 1.29% | +13.2% |
Q2 2020 | $21,968,000 | +27.8% | 124,235 | 0.0% | 1.14% | +2.5% |
Q1 2020 | $17,195,000 | -9.8% | 124,235 | 0.0% | 1.11% | +11.8% |
Q4 2019 | $19,068,000 | +1.1% | 124,235 | -4.9% | 0.99% | -1.2% |
Q3 2019 | $18,868,000 | +1.1% | 130,635 | 0.0% | 1.00% | +0.8% |
Q2 2019 | $18,670,000 | -10.9% | 130,635 | -17.7% | 1.00% | -9.6% |
Q1 2019 | $20,958,000 | +28.0% | 158,750 | 0.0% | 1.10% | +15.0% |
Q4 2018 | $16,370,000 | -5.1% | 158,750 | 0.0% | 0.96% | +12.6% |
Q3 2018 | $17,250,000 | +10.1% | 158,750 | 0.0% | 0.85% | +9.8% |
Q2 2018 | $15,665,000 | +0.8% | 158,750 | 0.0% | 0.77% | -2.1% |
Q1 2018 | $15,543,000 | +5.5% | 158,750 | 0.0% | 0.79% | +6.6% |
Q4 2017 | $14,735,000 | +8.2% | 158,750 | 0.0% | 0.74% | +3.3% |
Q3 2017 | $13,618,000 | -1.3% | 158,750 | -2.9% | 0.72% | -4.6% |
Q2 2017 | $13,802,000 | -1.3% | 163,550 | 0.0% | 0.75% | -3.0% |
Q1 2017 | $13,988,000 | +9.9% | 163,550 | 0.0% | 0.78% | +5.0% |
Q4 2016 | $12,731,000 | -0.7% | 163,550 | 0.0% | 0.74% | -0.5% |
Q3 2016 | $12,821,000 | -22.4% | 163,550 | 0.0% | 0.74% | -23.3% |
Q2 2016 | $16,519,000 | +6.5% | 163,550 | 0.0% | 0.97% | +5.0% |
Q1 2016 | $15,514,000 | +1.9% | 163,550 | -0.2% | 0.92% | +2.3% |
Q4 2015 | $15,218,000 | +9.0% | 163,850 | 0.0% | 0.90% | +1.3% |
Q3 2015 | $13,962,000 | -0.4% | 163,850 | 0.0% | 0.89% | +7.0% |
Q2 2015 | $14,024,000 | +0.8% | 163,850 | 0.0% | 0.83% | +1.1% |
Q1 2015 | $13,911,000 | -0.9% | 163,850 | 0.0% | 0.82% | -1.3% |
Q4 2014 | $14,044,000 | +12.8% | 163,850 | 0.0% | 0.83% | +10.0% |
Q3 2014 | $12,449,000 | -3.5% | 163,850 | 0.0% | 0.76% | -2.9% |
Q2 2014 | $12,900,000 | +5.0% | 163,850 | 0.0% | 0.78% | -0.6% |
Q1 2014 | $12,289,000 | -2.8% | 163,850 | 0.0% | 0.79% | -3.8% |
Q4 2013 | $12,649,000 | +11.4% | 163,850 | 0.0% | 0.82% | +0.9% |
Q3 2013 | $11,358,000 | +9.5% | 163,850 | 0.0% | 0.81% | +4.8% |
Q2 2013 | $10,372,000 | – | 163,850 | – | 0.77% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |